# A 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet

> **NCT01287091** · PHASE1 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 46 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** GDC-0980
- **DRUG:** GDC-0980
- **DRUG:** GDC-0980
- **DRUG:** GDC-0980
- **DRUG:** GDC-0980
- **DRUG:** GDC-0980
- **DRUG:** rabeprazole

## Key facts

- **NCT ID:** NCT01287091
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-14
- **Primary completion:** 2011-02-03
- **Final completion:** 2011-02-03
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2022-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01287091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01287091, "A 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01287091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*